Compare BV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BV | GLUE |
|---|---|---|
| Founded | 1939 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2018 | 2021 |
| Metric | BV | GLUE |
|---|---|---|
| Price | $12.14 | $10.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $15.35 | ★ $26.88 |
| AVG Volume (30 Days) | 813.3K | ★ 1.4M |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $3.21 | N/A |
| Revenue Next Year | $0.18 | N/A |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $9.82 | $9.68 |
| 52 Week High | $15.00 | $25.77 |
| Indicator | BV | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 75.26 | 42.12 |
| Support Level | $11.47 | $9.69 |
| Resistance Level | $12.59 | $12.00 |
| Average True Range (ATR) | 0.33 | 0.55 |
| MACD | 0.19 | 0.15 |
| Stochastic Oscillator | 92.68 | 40.54 |
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).